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Abstract
Background: The prevalence of allergic diseases is approximately 10 % in infants whose parents and siblings do
not have allergic diseases and 20–30 % in those with an allergic first-degree relative. Vitamin D is involved in the
regulation of the immune system and it may play a role in the development, severity and course of asthma and
other allergic diseases.
Objective: The World Allergy Organization (WAO) convened a guideline panel to develop evidence-based
recommendations addressing the use of vitamin D in primary prevention of allergic diseases.
Methods: Our WAO guideline panel identified the most relevant clinical questions and performed a systematic
review of randomized controlled trials and non-randomized studies (NRS), specifically cohort and case-control
studies, of vitamin D supplementation for the prevention of allergic diseases. We also reviewed the evidence about
values and preferences, and resource requirements (up to January 2015, with an update on January 30, 2016). We
followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to
develop recommendations.
Results: Having reviewed the currently available evidence, the WAO guideline panel found no support for the
hypothesis that vitamin D supplementation reduces the risk of developing allergic diseases in children. The WAO
guideline panel suggest not using vitamin D in pregnant women, breastfeeding mothers, or healthy term infants as
a means of preventing the development of allergic diseases. This recommendation does not apply to those
mothers and infants who have other indications for prophylactic or therapeutic use of vitamin D. The panel’s
recommendations are conditional and supported by very low certainty evidence.
Conclusions: WAO recommendations about vitamin D supplementation for the prevention of allergic diseases
support parents, clinicians and other health care professionals in their decisions whether or not to use vitamin D in
preventing allergic diseases in healthy, term infants.
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Executive summary
Approximately 10 % of children without an allergic par-
ent or sibling, and 20 to 30 % of those with allergies in
their first-degree relatives experience allergic diseases in
infancy. As demonstrated in cell culture and animal
model experiments, the active form of vitamin D, calci-
triol, is a modulator of both adaptive and innate immune
responses [1]. Nevertheless, its role is complex and not
completely understood. Additional studies relating to
vitamin D’s immunomodulating function suggest it may
impact the development of sensitization and allergy [2]
and therefore, if administered in sufficient doses, may
provide health benefits to humans by reducing a predis-
position to allergic diseases.
Methodology
The WAO-McMaster University guideline panel in-
cluded allergists, paediatricians, primary care physicians,
researchers in allergic diseases, and methodologists. We
used the GRADEpro (www.gradepro.org) software to
develop recommendations in this document following
the GIN-McMaster Guideline Development Checklist
(https://cebgrade.mcmaster.ca/guidecheck.html) and the
Grading of Recommendations, Assessment, Development
and Evaluation (GRADE) approach as applied to other
WAO guidelines [3–10]. Potential conflicts of interests
were managed as suggested by the World Health
Organization (WHO).
The guideline panel developed and graded the recom-
mendations, and assessed the certainty of the supporting
evidence (also called confidence in the estimates of
effects or quality of evidence). The certainty of the
evidence is categorized as high, moderate, low or very
low based on consideration of risk of bias, directness of
evidence, consistency and precision of the estimates, and
other considerations. Low and very low certainty
evidence indicates that the estimated effects of interven-
tions are very uncertain and any further research is very
likely to influence current recommendations.
Interpretation of strong and conditional
recommendations
The strength of recommendations is expressed as either
strong (guideline panel recommends…) or conditional
(guideline panel suggests…) and has the following
interpretation:
Strong recommendation
 For patients: most individuals in this situation would
want the recommended course of action, and only a
small proportion would not.
 For clinicians: most individuals should receive the
intervention. Adherence to this recommendation
according to the guideline could be used as a quality
criterion or performance indicator. Formal decision
aids are not likely to be needed to help individuals
make decisions consistent with their values and
preferences.
 For policy makers: the recommendation can be
adopted as policy in most situations.
Conditional recommendation
 For patients: the majority of individuals in this
situation would want the suggested course of action,
but many would not.
 For clinicians: recognize that different choices will
be appropriate for individual patients and that you
must help each patient arrive at a management
decision consistent with his or her values and
preferences. Decision aids may be useful in helping
individuals to make decisions consistent with their
values and preferences.
 For policy makers: policy-making will require
substantial debate and involvement of various
stakeholders.
How to use these guidelines
The GLAD-P guidelines about the use of vitamin D
provide the basis for rational, informed decisions for
clinicians, parents and other decision makers. Clinicians,
patients, third-party payers, institutional review commit-
tees, other stakeholders, or the courts should not view
these recommendations as dictates. No recommendation
can take into account all of the often-compelling unique
individual circumstances but provides guidance for
typical patients. Thus, no one charged with evaluating
health care professionals´ actions should apply the rec-
ommendations from these guidelines by rote or in a
blanket fashion.
Note: statements regarding the underlying values and
preferences as well as qualifying remarks accompanying
each recommendation are integral to the recommenda-
tions and serve to facilitate more accurate interpretation;
they should never be omitted when quoting recommen-
dations from these guidelines.
Recommendations
Question 1: Should vitamin D be used in pregnant
women?
Recommendation
The WAO guideline panel suggests that clinicians, par-
ents and other decision makers do not use vitamin D
supplementation in pregnant women with the intention
of preventing the development of allergic diseases in
their children (conditional recommendation, very low
certainty of evidence).
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Values and preferences
The recommendation not to use vitamin D in pregnant
women with the intention of preventing the develop-
ment of allergic diseases in their children places a rela-
tively higher value on avoiding additional cost and
burden and a relatively lower value on very uncertain, if
any, effect on prevention of allergic diseases.
Explanations and other considerations
Evidence does not support vitamin D supplementation in
pregnant women prevents the development of allergic dis-
eases in their children. This recommendation does not
apply to those pregnant women who have other indica-
tions for prophylactic or therapeutic use of vitamin D.
Question 2: Should vitamin D be used in breastfeeding
women?
Recommendation
The WAO guideline panel suggests that clinicians,
parents and other decision makers do not use vita-
min D supplementation in breastfeeding mothers
with the intention of preventing allergic diseases
their children (conditional recommendation, very low
certainty evidence).
Values and preferences
The recommendation to not use vitamin D in breast-
feeding mothers with the intention of preventing the de-
velopment of allergic diseases in their children places a
relatively higher value on avoiding additional cost and
burden and a relatively lower value on very uncertain, if
any, effect on prevention of allergic diseases.
Explanations and other considerations
Evidence does not support vitamin D supplementation
in breastfeeding mothers prevents the development of
allergic diseases in infants. This recommendation does
not apply to those breastfeeding women who have other
indications for prophylactic or therapeutic vitamin D
supplementation. This recommendation does not address
vitamin D supplementation for secondary prevention of
allergic diseases.
Question 3: Should vitamin D be used in infants?
Recommendation
The WAO guideline panel suggests that clinicians,
parents and other decision makers do not use vitamin D
supplementation in infants with the intention of pre-
venting the development of allergic diseases (conditional
recommendation, very low certainty evidence).
Values and preferences
The recommendation to not use vitamin D in healthy
term infants with the intention of preventing the
development of allergic diseases places a relatively
higher value on avoiding additional cost and burden and
a relatively lower value on very uncertain, if any, effect
on prevention of allergic diseases.
Explanations and other considerations
Evidence does not support vitamin D supplementation
in infants prevents the development of allergic diseases.
This recommendation does not apply to infants who
have other indications for prophylactic or therapeutic
vitamin D supplementation. This recommendation does
not address vitamin D supplementation for secondary
prevention of allergic diseases.
Scope and purpose
The purpose of this document is to evaluate the current
evidence and provide guidance on the use of vitamin D
for the primary prevention of allergic diseases focusing
on asthma and/or wheezing, allergic rhinitis, atopic ec-
zema (dermatitis), and food allergy. The target audiences
for these guidelines are general practitioners, pediatri-
cians, specialists in allergic disease and immunology, re-
spiratory medicine specialists, obstetrician/gynaecologists,
and dermatologists managing pregnant women and in-
fants at risk of developing allergic diseases. General inter-
nists, and other health care professionals and policy
makers may also benefit from these guidelines. Policy
makers interested in these guidelines include those in-
volved in developing local, national or international pol-
icies that have the goal of reducing the incidence of
allergic diseases, and limiting the direct and indirect costs
of allergic diseases [11]. This document may also serve as
the basis for development and implementation of locally
adapted guidelines.
Introduction
Allergic diseases represent a spectrum of health condi-
tions with a large worldwide burden. In infants, its inci-
dence is highly influenced by the allergic status of their
parents: approximately 10 % in infants without an allergic
parent or sibling, versus approximately 20 to 30 % in those
with an atopic history in their first-degree relatives [12].
A growing body of literature has addressed associa-
tions between vitamin D concentrations and various
conditions. Observational studies and randomized trials
have addressed the possible effectiveness of vitamin D
supplementation in the prevention or treatment of a var-
iety of disorders and adverse health outcomes. Emerging
evidence indicates that vitamin D may play a role in the
immune system. In particular, the active form of vitamin
D, calcitriol, has been shown to modulate immune func-
tioning in cell culture and animal models [13]. Neverthe-
less, understanding of the complex role of vitamin D in
immune function remains limited [14].
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The Guidelines for Atopic Disease Prevention (GLAD-
P) is a joint effort of the World Allergy Organization
(WAO) and the Department of Clinical Epidemiology &
Biostatistics at McMaster University to evaluate the
current evidence addressing the preventive effect of pro-
biotics, prebiotics, and vitamin D on allergic diseases
and related patient-important outcomes. This document
provides recommendations on the rationale for use of
vitamin D.
We use the following definitions throughout the
document:
 Vitamin D supplement: any formulation of vitamin D,
either alone or in multi-vitamin products, including
products available by prescription or over the counter,
and food supplements available from pharmacies and
retail outlets [15].
 Family history influencing risk for allergic diseases in
a child: biological parent or sibling with existing or
history of allergic rhinitis, asthma, eczema, or food
allergy [16].
Methods
Panel composition and meetings
We followed the procedures and methodology using the
GIN-McMaster Guideline Development Checklist, the
GRADE approach and methods we had previously
applied to WAO guidelines [3–9]. Under the auspices of
the organizations, we assembled a team of experts in-
cluding allergists, pediatricians, and family physicians
and representatives of the general public. The guideline
panel included methodologists who helped to prepare
systematic reviews and evidence summaries.
A face-to-face meeting was held in January 2015 coin-
ciding with the WAO Symposium in Rome, Italy. During
the meeting the guideline panel discussed specific ques-
tions in the context of existing research evidence to
make recommendations.
Disclosure of potential conflicts of interest
Guideline panel members disclosed all potential conflicts
of interest according to the World Health Organization
policies. The chairs (AF, RP and HJS) reviewed and
resolved all potential conflicts of interest of panel mem-
bers (see Additional file 1 for the list of declared con-
flicts of interest for all panel members). During all
deliberations, panel members with potential conflicts of
interest abstained from decisions about recommenda-
tions related to their potential conflict of interest.
WAO provided meeting facilities during the Sympo-
sium and financial support to perform systematic re-
views. The views and interests of the WAO as well as
any commercial entity that provided external funding to
WAO had no influence on the final recommendations.
Formulating specific clinical questions and determining
outcomes of interest
We used the electronic tools: GRADEpro Guideline
Development Tool (www.gradepro.org) [17] and Survey-
Monkey (https://www.surveymonkey.com/) to brainstorm
and subsequently prioritize questions related to the use of
vitamin D for the prevention of allergic diseases.
The following questions were prioritized and addressed
in this document:
1. Should vitamin D versus no vitamin D be used in
pregnant women?
2. Should vitamin D versus no vitamin D be used in
women who are breastfeeding?
3. Should vitamin D versus no vitamin D be used in
infants?
The guideline selected outcomes of interest for each
question, following the approach suggested by the
GRADE Working Group [3]. All outcomes were iden-
tified a priori and the panel explicitly rated their
relative importance for decision-making. Ranking
outcomes by their relative importance can help focus
attention on the outcomes that are considered most
important and help to resolve or clarify potential
disagreements.
Evidence review and development of clinical
recommendations
Evidence summaries for each question were prepared
by the methodologists (JJYN, CCG, JB and HJS) using
GRADEpro GDT (www.gradepro.org). All guideline
panel members reviewed the summaries of evidence
and made corrections when appropriate. We based
the evidence summaries on a systematic review of the
literature performed specifically for these guidelines.
(Reference. in preparation). An updated search strat-
egy (presented in the online Additional file 2) was
performed on January 30, 2016 that provided two
additional studies. We followed the methods of the
Cochrane Collaboration (handbook.cochrane.org) and
assessed the risk of bias at the outcome level using
the Cochrane Collaboration’s risk of bias tool [18],
and version 1.0 of the Cochrane Risk of Bias Assess-
ment Tool for Non-Randomized Studies of Interven-
tions, now called ROBINS-I [19], for RCTs and NRSs,
respectively. Subsequently, we assessed the certainty
of the body of evidence (confidence in the estimated
effects) for each of the outcomes of interest using the
GRADE approach based on the consideration of risk
of bias, directness of evidence, consistency and preci-
sion of the estimates, and other factors such as publi-
cation bias.
Yepes-Nuñez et al. World Allergy Organization Journal  (2016) 9:17 Page 4 of 12
We searched for evidence about values and prefer-
ences and cost of vitamin D supplementation. We pre-
pared the evidence-to decision frameworks based on the
estimates of the health effects, values and preferences,
and resource use.
During the meeting, the guideline panel developed
recommendations based on the evidence summaries and
the evidence-to-decision frameworks. For each recom-
mendation, the guideline panel considered and agreed
on the following: the certainty of the evidence, the bal-
ance of desirable and undesirable consequences of com-
pared management options, the feasibility, acceptability
and impact on health inequities for each recommenda-
tion, as well as the assessment of the values and prefer-
ences associated with the decision. The guideline panel
also explicitly took into account the possible extent of
resource use associated with alternative management
options.
Recommendations and their strength were developed
through consensus and no recommendation required
voting. The panel agreed on the final wording of recom-
mendations and remarks with further qualifications for
each recommendation.
We labelled the recommendations as either “strong”
or “conditional” according to the GRADE approach. We
used the words “the panel members recommend” for
strong recommendations and “suggest” for conditional
recommendations. Table 1 provides suggested interpret-
ation of strong and conditional recommendations.
Document review
Each member of the guideline panel reviewed the final
draft document and approved the document, which was
then submitted to the WAO for peer review. The docu-
ment was revised to incorporate the pertinent comments
suggested by the external reviewers.
How to use these guidelines
The WAO-McMaster University GLAD-P guidelines
about the use of vitamin D in the primary prevention of
allergic diseases in children are not intended to impose a
standard of care. They provide the basis for rational de-
cisions. Clinicians, patients, third-party payers, institu-
tional review committees, other stakeholders, or the
courts should never view these recommendations as dic-
tates. No recommendation can take into account all of
the often-compelling unique circumstances of each indi-
vidual patient. Therefore, no one charged with evaluat-
ing health care professionals’ actions should apply the
recommendations from these guidelines as rote or in a
blanket fashion.
Statements regarding the underlying values and prefer-
ences as well as qualifying remarks accompanying each
recommendation are integral parts and serve to facilitate
more accurate interpretation. They should never be
omitted when quoting recommendations from these
guidelines.
Recommendations
Question 1. Should vitamin D versus no vitamin D be
used in pregnant women?
Summary of the evidence
We found no systematic review addressing this question.
We found seven publications [reporting six randomized
control trials (RCTs)] that investigated the effects of
vitamin D supplementation in pregnant women. Only
one RCT [20] measured the risk of developing allergic
diseases in children, and the remaining trials [21–27] re-
ported nutritional status, adverse effects, and develop-
ment of rickets. No study reported quality of life and
development of a composite of “any allergy”. We also
found two observational studies, one case-control and
one cohort study, which reported the effect of vitamin D
supplementation in pregnant women on the develop-
ment of food allergy and wheezing in their infants re-
spectively [28, 29].
The randomized trial failed to detect an effect of vita-
min D supplementation on the risk of developing aller-
gic diseases in children: atopic dermatitis (RR 0.96, 95 %
CI 0.57 to 1.61), allergic rhinitis (RR 0.76, 95 % CI 0.31
to 1.85), asthma and/or wheezing (RR 1.12, 95 % CI 0.50
to 2.54), and food allergy (RR 1.92, 95 % CI 0.57 to
Table 1 Interpretation of strong and conditional recommendations
Implications for: Strong recommendation Conditional recommendation
Patients Most individuals in this situation would want the
recommended course of action, and only a small
proportion would not.
The majority of individuals in this situation would want
the suggested course of action, but many would not.
Clinicians Most individuals should receive the intervention.
Adherence to this recommendation according to
the guideline could be used as a quality criterion
or performance indicator. Formal decision aids are
not likely to be needed to help individuals make
decisions consistent with their values and preferences.
Recognize that different choices will be appropriate for
individual patients and that you must help each patient
arrive at a management decision consistent with his or
her values and preferences. Decision aids may be useful
in helping individuals to make decisions consistent with
their values and preferences.
Policy makers The recommendation can be adopted as policy
in most situations.
Policymaking will require substantial debate and
involvement of various stakeholders.
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6.50). Vitamin D supplementation in pregnant women
was not associated with a lower birth weight in infants
compared to no vitamin D (mean difference 52.78 g
more, 95 % CI -64.34 to 169.90). Adverse effects as mea-
sured by infants being born small for gestational age,
gestational age, symptomatic hypocalcaemia, as well as
severe adverse effects in a newborn and in the mother
were very infrequent and any estimates are very impre-
cise. There was no difference between the groups.
The findings of the case-control study were consistent
with the findings of the randomized trial for food allergy
(OR 1.50, 95 % CI 0.78 to 2.88). In the cohort study,
vitamin D was associated with low risk of developing
wheezing (OR 0.65, 95 % CI 0.46 to 0.93). The overall
certainty of the body of evidence was very low owing to
the risk of bias and imprecision. Online Additional file 3
presents the characteristics of all included studies for all
questions.
Benefits
Thus far, there is no direct evidence from clinical studies
suggesting that vitamin D supplementation during preg-
nancy reduces the risk of developing allergic diseases in
children (see evidence profile for question 1 in the Add-
itional file 4).
Harms and burden
Adverse effects in pregnant women were well defined in
all studies. Abnormal glucose challenge test was re-
ported as an adverse effect in one study [22]. Other ad-
verse effects included nausea and vomiting [26].
Maternal serious adverse effects included gastroenteritis,
preterm delivery with premature rupture of membranes,
injury, and pre-eclampsia. For pregnant women with ad-
verse effects and serious adverse effects, there was no
difference among those who received vitamin D and
those who did not receive vitamin D (RR 1.46, 95 % CI
0.31 to 6.78; RR 1.55, 95 % CI 0.65 to 3.69 respectively).
The certainty in the estimate of the risk of adverse
events in pregnant mothers ranged between low to very
low due to the development of few events in both arms.
Adverse effects in infants were well documented and
included low birth weight (assessed in grams), gesta-
tional age (preterm labour), small for gestational age
(assessed as weight lower than 10th centile or less than
2.5 kg) (RR 0.67, 95 % CI 0.37 to 1.19), hypocalcaemia
(RR 0.10, 95 % CI 0.01 to 1.82), any and serious adverse
effects (RR 0.79, 95 % CI 0.33 to 1.90). No adverse
effects related to the administration of vitamin D in in-
fants were reported in two studies [20, 21]. Serious ad-
verse effects included hypoxic-ischemic encephalopathy,
meconium aspiration syndrome, jaundice, neonatal sei-
zures, sepsis, sub-acute intestinal obstruction, pneumo-
nia, intrauterine, and neonatal death. In total, three
intrauterine and four neonatal deaths (two and one
deaths in the vitamin D group respectively) were re-
ported. Reasons for intrauterine deaths were not speci-
fied. A preterm infant with very low birth weight, died
within 5 min of birth at home (placebo group). The rea-
sons for other neonatal deaths were sepsis and multi-
organ failure, severe hypoxic-ischemic encephalopathy
and respiratory failure, cardio-respiratory failure of un-
known etiology. Adverse effects were not different
among infants who received vitamin D and those who
did not receive vitamin D. The certainty of the evidence
of adverse effects in infants ranged between moderate
(gestational age, birth weight), low (weight at 1 year, any,
and serious adverse events), and very low (small for ges-
tational age, symptomatic hypocalcaemia). The certainty
in the estimates was assessed as moderate and low
confidence due to imprecision in the estimates. Very low
certainty in the estimates was downgraded due to impre-
cision and risk of bias.
Decision criteria and considerations
The values and preferences of women regarding the use
of vitamin D during pregnancy are likely dependent on
cultural and socioeconomic background. We explicitly
considered the required resources. Prices of vitamin D
are likely to vary depending on the factors such as coun-
try, region or formulation. The literature review did not
identify any cost-effectiveness analysis related to the pre-
ventive use of vitamin D for allergic diseases.
Conclusions and research needs
The guideline panel determined that it is unlikely that
there is a net benefit from using vitamin D in pregnant
women who have no specific indications for prophylactic
or therapeutic vitamin D supplementation and the only
purpose would be to primary prevention of allergic dis-
eases in their children. We found no impact of vitamin D
on the development of allergic diseases. There is a need
for a rigorously designed and executed randomized trial of
vitamin D supplementation in pregnant women that
would properly measure and report patient-important
outcomes, including development of allergic diseases,
quality of life, and adverse effects. Long-term follow-up of
such studies to evaluate long-term effects is also needed.
What others are saying
We found no guidelines that made specific recommen-
dations about the use of vitamin D in pregnancy with
the intention of preventing allergic diseases in children.
The World Health Organization (WHO) states “Vitamin
D supplementation is not recommended during preg-
nancy to prevent the development of pre-eclampsia and
its complications (strong recommendation). In addition,
due to the limited evidence currently available to directly
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assess the benefits and harms of the use of vitamin D
supplementation alone in pregnancy for improving ma-
ternal and infant health outcomes, the use of this inter-
vention during pregnancy as part of routine antenatal
care is also not recommended (conditional recommen-
dation) [30]”.
The National Institute for Health and Care Excellence
(NICE) recommends increasing the access to vitamin D
supplements in high risk groups that have a low vitamin
D status such as pregnant and breastfeeding women,
particularly teenagers and young women [15]. The
American Academy of Pediatrics (AAP) [31] recom-
mends, on an individual basis, pregnant women should
receive adequate amounts of vitamin D3 to ensure that
her 25-OH-D levels are sufficiently high (>80 nmol/L).
Similarly, the Endocrine Society Clinical Practice Guide-
line [32] states that pregnant women require adequate
supplementation of vitamin D so that vitamin D levels
are not insufficient.
The European Society for Paediatric Gastroenterology,
Hepatology, and Nutrition Committee on Nutrition [33],
the European Academy of Allergy and Clinical Immun-
ology [34], Food Allergy and Anaphylaxis Guidelines
[35] and the Guidelines from the US National Institute
of Allergy and Infectious Diseases [16], make no specific
recommendations regarding the use of vitamin D in
pregnant women.
Recommendation 1
The WAO guideline panel suggests that clinicians, parents
and other decision makers do not use vitamin D supple-
mentation in pregnant women with an intention to prevent
development of allergic diseases in their children (condi-
tional recommendation, very low certainty of evidence).
Values and preferences
The recommendation not to use vitamin D in pregnant
women with the intention of preventing the develop-
ment of allergic diseases in their children places a rela-
tively higher value on avoiding additional cost and
burden and a relatively lower value on very uncertain, if
any, effect on prevention of allergic diseases.
Explanations and other considerations
Evidence does not support vitamin D supplementation
in pregnant women prevents the development of allergic
diseases in their children. This recommendation does
not apply to those pregnant women who have other in-
dications for prophylactic or therapeutic use of vitamin
D. See the evidence to recommendation table for ques-
tion 1 in online Additional file 5.
Question 2. Should vitamin D versus no vitamin D be
used in breastfeeding mothers?
Summary of the evidence
We found no systematic review or randomized trial of
vitamin D supplementation in breastfeeding mothers
that reported on the development of allergic diseases in
children. We identified one case-control study which
addressed this question and found no effect of vitamin
D supplementation in breastfeeding mothers on the risk
of developing asthma and/or wheezing in children: (OR
1.09, 95 % CI 0.84 to 1.40) [36].
One RCT [37] reported no cases of rickets among 60
children of breastfeeding mothers that either used or
didn’t use vitamin D supplements. The time of follow-
up was 6 weeks, which was considered too short to de-
velop this outcome. No experimental or observational
study with an independent control group reported other
outcomes of interest. Adverse effects were not reported
in the included studies. The overall certainty of the body
of evidence was very low.
Benefits
There is no evidence from clinical studies suggesting an
effect of vitamin D supplementation in breastfeeding
mothers on the risk of developing allergic diseases in
children (see evidence profile for question 2 in the Add-
itional file 4).
Harms and burden
Any estimate of potential adverse effects is very uncer-
tain due to the unavailability of reports of adverse
effects.
Decision criteria and considerations
The panel agreed that the considerations of values and
preferences, resource implications, and equity are likely
similar to those in pregnant women.
Conclusions and research needs
The guideline panel determined that it is not possible to
determine whether there is any benefit from using vita-
min D supplementation in breastfeeding women who
have no specific indications for prophylactic or thera-
peutic vitamin D supplementation for the sole purpose
of reducing the risk of developing allergic diseases in
otherwise healthy term children. Given the paucity of in-
formation, it is not possible to exclude an appreciable
benefit, no effect or appreciable harm.
There is a need for a rigorously designed and well-
executed randomized trial of vitamin D in breastfeeding
women that would properly measure and report patient-
important outcomes, including quality of life and ad-
verse effects. Long-term follow-up of such studies to
evaluate long-term effects is also needed.
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What others are saying
We found no guidelines that made specific recommen-
dations about the use of vitamin D in breastfeeding
mothers with the intention of preventing allergic dis-
eases in children. The AAP [31] does not recommend
supplementing breastfeeding mothers with high doses of
vitamin D in order to increase the 25-OH-D concentra-
tions in their breastfed infants. However, they recommend,
“a supplement of 400 IU/day of vitamin D should begin
within the first few days of life and continue throughout
childhood”. NICE [15] recommends increasing the access
to vitamin D supplements in high risk groups of low vita-
min D status such as pregnant and breastfeeding women,
particularly teenagers and young women. ESPGHAN [33],
considering the prevalence of vitamin D deficiency in
pregnant mothers, recommends that a higher vitamin
D supply in preterm infants could be necessary in
order to correct the foetal low plasma level. This
statement holds for both premature infants fed
mother’s milk and those fed formula milk.
WHO [30], the Endocrine Society Clinical Practice
Guideline [32], the European Academy of Allergy and
Clinical Immunology [34] Food Allergy and Anaphylaxis
Guidelines [35] and the Guidelines from the US National
Institute of Allergy and Infectious Diseases [16], make
no specific recommendations about the use of vitamin D
in breastfeeding women.
Recommendation 2
The WAO guideline panel suggests that clinicians,
parents and other decision makers do not use vitamin
D supplementation in breastfeeding mothers with the
intention of preventing allergic diseases in their chil-
dren (conditional recommendation, very low certainty
evidence).
Values and preferences
This recommendation not to use vitamin D in breast-
feeding mothers with an intention of preventing the de-
velopment of allergic diseases in their children places a
relatively higher value on avoiding additional cost and
burden and a relatively lower value on very uncertain, if
any, effect on prevention of allergic diseases.
Explanations and other considerations
Evidence does not support that vitamin D supplementa-
tion in breastfeeding mothers prevents the development
of allergic diseases in infants. This recommendation does
not apply to those breastfeeding women who have other
indications for prophylactic or therapeutic vitamin D sup-
plementation. This recommendation does not address
vitamin D supplementation for secondary prevention of
allergic diseases. See the evidence to recommendation
table for question 2 in online Additional file 5.
Question 3. Should vitamin D vs. no vitamin D be used in
healthy infants?
Summary of the evidence
We found no systematic review addressing this question.
We found 5 randomized trials that investigated vitamin
D supplementation in infants but none reported allergy
outcomes [38–42]. One RCT [42] could not be meta-
analyzed because it reported mean values without mea-
sures of dispersion. We identified three NRS. Two co-
hort studies reported the risk of developing allergic
rhinitis and asthma [43], and wheezing/asthma [29]. The
case control study measured development of food allergy
[28]. No study measured quality of life and development
of eczema or a composite of “any allergy”.
In the first cohort study [43], regular vitamin D sup-
plementation during the first year of life increased the
risk of developing allergic rhinitis (RR 1.95, 95 % CI 0.69
to 5.54) but there were only three events among 20 chil-
dren in the control group, which makes these results
very fragile and very imprecise. Study authors combined
the group that never received vitamin D with a group
that used it irregularly to reduce fragility of the results –
if those using vitamin D regularly were compared with
those who either did not use it, or used it irregularly, the
RR would be 1.31 (95 % CI 1.15 to 1.49). Irrespective of
the choice of control group, there is a high risk of bias
in these estimates, because results were not adjusted for
confounding factors despite the fact that “cohort mem-
bers with a family history of asthma were less likely to
receive supplementation according to recommendations
(…) and many of the same characteristics that were pre-
dictive of worse compliance were associated with re-
duced risk of allergies” [43]. In the same study, the risk
of developing asthma and/or wheezing was estimated
too imprecisely to make any conclusion about the effect
(RR 3.07, 95 % CI 0.19 to 50.88). If those using vitamin
D regularly were compared with those who either did
not use it or used it irregularly, the RR would be 1.36
(95 % CI 1.00 to 1.85). The certainty of the evidence for
these two outcomes was very low.
The second cohort study [29] did not show an effect
in the primary prevention of asthma/wheezing in infants
if they were exposed to vitamin D supplementation dur-
ing their chilhood (OR 1.00, 95 % CI 0.81 to 1.23).
In the case-control study the risk of developing food
allergy during the first year of life was reduced in infants
who received vitamin D compared to those who did not
(OR 0.49, 95 % CI 0.27 to 0.88) [28]. However, the confi-
dence in this estimate is also very low owing to indirect-
ness of the evidence and risk of bias.
Four RCTs reported the estimation of developing rick-
ets. None of the infants in these four studies developed
rickets. One RCT reported weight at one year of age
without significant differences between those infants
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who received vitamin D and those who did not receive
vitamin D. Information about weight was available only
graphically. The certainty of evidence ranged between
low to very low owing to imprecision, risk of bias, and
indirectness.
Adverse effects were reported in three RCTs. These
adverse effects included inter-current acute diseases, and
urinary tract infection. As a serious adverse effect, one
study reported a sudden infant death syndrome, which
was not related to the trial. Adverse effects and serious
adverse effects were not different among infants who re-
ceived vitamin D and those who did not receive vitamin
D (RR 0.85, 95 % CI 0.23 to 3.14; RR 0.17, 95 % CI 0.01
to 3.70 respectively). The certainty of the evidence was
very low due to serious risk of bias and imprecision.
No RCT or NRS addressed the efficacy or association
of primary prevention of allergic diseases in children
(over 2 years old) after vitamin D supplementation.
Benefits
There is a probable reduction in the risk of developing
food allergy in infants during the first year of life (RR:
0.49, 95 % CI: 0.27 to 0.88) with vitamin D supplementa-
tion. There is no evidence supporting a reduction in the
risk of developing any other allergic disease in infants
(see evidence profile for question 3 in the Additional file
4).
Harms and burden
Regular vitamin D supplementation during the first year
of life increased the risk of developing allergic rhinitis
(RR 1.95, 95 % CI 0.69 to 5.54), and asthma and/or
wheezing (RR 3.07, 95 % CI 0.19 to 50.88; OR 1.00, 95 %
CI 0.81 to 1.23) but the certainty of the evidence is very
low.
Decision criteria and considerations
If vitamin D is used in infants, it is not clear when it
should be started and how long it should be used and
there is an uncertainty about the dosage.
The previous considerations concern otherwise healthy
infants in whom vitamin D would be used for pri-
mary prevention of allergic diseases. They do not
concern using vitamin D for specific indications, e.g.,
preterm infants, especially with birth weight <1800 to
2000 g [35].
Conclusions and research needs
The guideline panel determined that net benefit from
using vitamin D in infants is uncertain. There is a need
for rigorously designed and well executed randomized
trials of vitamin D in infants that would measure and
adequately report patient-important outcomes, including
adverse effects.
What others are saying
We found no guidelines that made specific recommen-
dations about the use of vitamin D in infants with the
intention of preventing development of allergic diseases.
NICE [15] recommends increasing the access to vitamin
D supplements in high risk groups of low vitamin D sta-
tus such as infants and children aged under 5. AAP [31]
recommends that “infants who receive a mixture of hu-
man milk and formula also should get a vitamin D sup-
plement of 400 IU/day to ensure an adequate intake.
Additionally, “any infant who receives <1 L or 1 qt of
formula per day needs an alternative way to get 400 IU/day
of vitamin D, such as through vitamin supplements”. The
Endocrine Society Clinical Practice Guideline [32]
suggests that infants and children age 0-1 year re-
quire an intake of vitamin D of at least 400 IU/d,
and children 1 year and older, at least 600 IU/d to
maximize bone health. ESPGHAN [39] recommends
that, considering the prevalence of vitamin D defi-
ciency in pregnant mothers, higher vitamin D supply
in preterm infants could be necessary to rapidly cor-
rect the foetal low plasma level. A vitamin D intake
of 800 to 1000 IU/day (and not per kilogram) during
the first months of life is recommended. WHO [30]
and the European Academy of Allergy and Clinical
Immunology Food Allergy and Anaphylaxis Guideline
[35] make no specific recommendations about the use
of vitamin D in infants.
Recommendation 3
The WAO guideline panel suggests that clinicians, par-
ents and other decision makers do not use vitamin D
supplementation in infants with an intention to prevent
development of allergic diseases (conditional recommen-
dation, very low certainty evidence).
Values and preferences
This recommendation to not use vitamin D in healthy
term infants with the intention of preventing the devel-
opment of allergic diseases places a relatively higher
value on avoiding additional cost and burden and a rela-
tively lower value on very uncertain, if any, effect on
prevention of allergic diseases.
Explanations and other considerations
Evidence does not support that vitamin D supplementa-
tion in infants prevents the development of allergic
diseases. This recommendation does not apply to
infants who have other indication for prophylactic or
therapeutic vitamin D supplementation. This recom-
mendation does not address vitamin D supplementa-
tion for secondary prevention of allergic diseases. See
the evidence to recommendation table for question 3
in online Additional file 5.
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Priorities for revision of the guidelines
Plans for updating these guidelines To remain useful,
guidelines need to be updated regularly as new informa-
tion accumulates. A revision of this document will be
needed, because there was limited evidence for the three
clinical questions.
This document will be updated when major new re-
search is published. As it was stated before, this guide-
line was focused on primary prevention. However we
will look at secondary prevention in the next update of
this guideline. The need for updates will be determined
no later than in 2019.
Updating or adapting recommendations locally The
methods used to develop these guidelines are transpar-
ent. The recommendations have been developed to be as
specific and detailed as possible without losing sight of
the desirability of simplicity. Since GLAD-P guidelines
are meant as international guidelines, the panel encour-
ages feedback on all aspects including their applicability
in individual countries. The panel will consider this feed-
back when revising the document.
Adaptation of these guidelines will be necessary in
many circumstances. Depending on when such a process
takes place, the following steps should be taken:
 Appointing a guideline committee comprised of
clinicians and methodologists.
 Determining the scope of the localized guidelines.
 Defining the clinical questions to be addressed.
 Updating the evidence profiles and evidence-to
decision frameworks, if necessary.
 Reviewing the recommendations in the GLAD-P
guidelines (the recommendations may need to be
modified at a local level, depending on the local values
and preferences, availability of medications, costs, etc.).
 Disseminating the guidelines, with a clear “use by” date.
 Developing a method to obtain feedback and plans
for review and update.
Priorities for research
During the guideline development process we identified
a need for more data on specific topics. This results in the
following recommendations for research. We summarize
these gaps in the evidence as research recommendations,
to assist those in a position to provide such information
by the design and execution of specific research projects.
Specific research needs to be addressed:
 Development of clinical prediction guides for
evaluating the risk of allergic diseases in children
(the family history predicts only about 30 % of the
population risk).
 Evaluation of effects of using vitamin D in
breastfeeding mothers specifically in that period
(as opposed to intervention administered during
pregnancy and to children).
 Evaluation of the effects of different ways of
administering vitamin D, e.g., as milk or dairy
supplements, stand-alone supplements, etc.
 Performance of rigorously designed, adequately
powered, and well executed randomized trials of
vitamin D in infants who did not receive vitamin D
prenatally and/or during breastfeeding; studies
should include infants considered to be at high and
low/average risk for allergic diseases and should
properly report patient-important outcomes, including
adverse effects. The estimated optimal information size
for this question is from approximately 2500
participants (for eczema) to 27,000 participants
(for food allergy). However, for the evaluation of
adverse effects, a large compilation of RCTs as
well as observational studies might be necessary
with thousands of observations.
 Evaluation addressing which of the 3 populations
(pregnant women, breastfeeding mothers, and
infants) should receive vitamin D – whether there is
a larger benefit with supplementation in one or a
combination of these populations and, if so, which
populations to target.
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